Teva Pharmaceutical Industries (TEVA)
(Real Time Quote from BATS)
$10.37 USD
+0.03 (0.29%)
Updated Aug 19, 2022 10:56 AM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
TEVA 10.37 +0.03(0.29%)
Will TEVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TEVA
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
Why Is Bausch (BHC) Down 11.2% Since Last Earnings Report?
Other News for TEVA
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business HighlightsÂ
States reach deal over marketing, safety of generic opioids
Bausch Health down another 10% after Thursday plummet on Xifaxan patent order
Bausch Health down another 10% after Thursday plummet on Xifaxan patent order
Bausch Health down another 10% after Thursday plummet on Xiafxan patent order